IP Verse

Dr. Falk Pharma Gmbh competitive analysis

Latest oppositions filed by Dr. Falk Pharma Gmbh

Explore patent oppositions filed by Dr. Falk Pharma Gmbh against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP3574914
Corticosteroid CompositionsMERITAGE PHARMASep 1, 2022
EP2585075
Methods Of Treatment For Esophageal InflammationMERITAGE PHARMAMay 4, 2022
EP2646003
Rapidly Dispersing Granules, Orally Disintegrating Tablets And MethodsADARE PHARMACEUTICALSFeb 23, 2021
EP3354276
Compositions For The Treatment Of Gastrointestinal InflammationMERITAGE PHARMASep 23, 2020
EP3041476
Corticosteroid Containing Orally Disintegrating Tablet Compositions For Eosinophilic EsophagitisADARE IJul 22, 2020
EP3403654
Orally Administered Corticosteroid CompositionsADARE IApr 28, 2020
EP2214679
Corticosteroid CompositionsMERITAGE PHARMADec 19, 2019
EP2482822
Orally Administered Corticosteroid CompositionsADARE IMar 1, 2019
EP2211896
Compositions For The Treatment Of Gastrointestinal InflammationMERITAGE PHARMASep 27, 2018
EP2214677
Compositions For The Treatment Of Inflammation Of The Gastrointestinal TractMERITAGE PHARMAMay 22, 2018

Latest patents of Dr. Falk Pharma Gmbh opposed by its competitors

Explore Dr. Falk Pharma Gmbh's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP2886108
Nov 2, 2022Optimised Pharmaceutical Formula For The Treatment Of Inflammatory Changes Of The Esophagus2
EP3086782
Sep 26, 2018Optimized Pharmaceutical Formulation For The Treatment Of Inflammatory Conditions Of The Esophagus2

Latest PTAB cases involving Dr. Falk Pharma Gmbh

Discover the latest PTAB cases involving Dr. Falk Pharma Gmbh, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 26, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Dr. Falk Pharma Gmbh

PGR2025-00086Sep 19, 2025DR. FALK PHARMA GMBHELLODI PHARMACEUTICALSTerminated
IPR2025-00052Oct 24, 2024DR. FALK PHARMA GMBHELLODI PHARMACEUTICALS LPTerminated-Adverse Judgment
IPR2025-00054Oct 24, 2024DR. FALK PHARMA GMBHELLODI PHARMACEUTICALS LPTerminated-Adverse Judgment
IPR2025-00055Oct 24, 2024DR. FALK PHARMA GMBHELLODI PHARMACEUTICALS LPTerminated-Adverse Judgment
IPR2025-00056Oct 24, 2024DR. FALK PHARMA GMBHELLODI PHARMACEUTICALS LPTerminated-Adverse Judgment
IPR2024-01197Jul 22, 2024DR. FALK PHARMA GMBHELLODI PHARMACEUTICALS LPTerminated-Adverse Judgment

Peer Comparison New

IP litigation analysis comparing Dr. Falk Pharma Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DR. FALK PHARMA GMBH1046 -
ADARE PHARMACEUTICALS US, L.P.23 - -
ELLODI PHARMACEUTICALS LP - - - 5
MERITAGE PHARMA - 10 - -